Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders.

Abstract

Objective: To determine whether genetic variants in a pharmacokinetic gene (the number of CYP2C19 reduced function alleles [RFAs]), and in pharmacodynamic genes (HTR2A, SLC6A4, and GRIK4) influence sertraline tolerability and response in a cohort of pediatric patients with anxiety and depressive disorders. Methods: A retrospective analysis was performed using the electronic medical record data of 352 patients <19 years of age being treated for anxiety and/or depressive disorders with sertraline and who underwent routine clinical CYP2C19 genotyping. Additional genotyping and analysis of variants in HTR2A, SLC6A4, and GRIK4 were conducted for 249 patients. Multivariate regression models testing for associations with CYP2C19 were adjusted for concomitant use of interacting medications. Combinatorial classification and regression tree (CART) analyses containing all pharmacokinetic and pharmacodynamic genes and clinical factors were performed. Results: The maximum sertraline dose during the initial titration period of sertraline was inversely associated with the number of CYP2C19 RFAs and sertraline dose at 60 (p = 0.025) and 90 days (p = 0.025). HTR2A rs6313 was associated with sertraline dose (p = 0.011) and time to the average maximum sertraline dose (p = 0.039). Regarding efficacy, the number of CYP2C19 RFAs was not associated with the sertraline dose at the time of response (p = 0.22), whereas for the pharmacodynamic genes, only HTR2A rs6313 was associated with response dose (p = 0.022). An association was observed between predicted expression levels of SLC6A4 and the duration on sertraline (p = 0.025). Combinatorial CART and multivariate regression analyses implicated that pharmacodynamic genes and clinical factors influence the maximum sertraline dose and response dose. The total number of side effects was not associated with any of the variants tested. Conclusion: Both pharmacokinetic and pharmacodynamic factors, in addition to clinical and demographic components, influence sertraline dose, response, and tolerability, thereby necessitating further research to assess for the validity of these pharmacogenetic associations in children and adolescents.

• Authors: Ethan A Poweleit, Stacey L Aldrich, Lisa J Martin, David Hahn, Jeffrey R Strawn, Laura B Ramsey
• Journal: Journal of child and adolescent psychopharmacology (J Child Adolesc Psychopharmacol) Vol. 29 Issue 5 Pg. 348-361 (06 2019) ISSN: 1557-8992 [Electronic] United States
• PMID: 31066578 (Publication Type: Journal Article)

Chemical References

• Antidepressive Agents
• GRIK4 protein, human
• HTR2A protein, human
• Receptor, Serotonin, 5-HT2A
• Receptors, Kainic Acid
• SLC6A4 protein, human
• Serotonin Plasma Membrane Transport Proteins
• CYP2C19 protein, human
• Cytochrome P-450 CYP2C19
• Sertraline

Topics

• Adolescent
• Antidepressive Agents (therapeutic use)
• Anxiety Disorders (drug therapy, genetics)
• Child
• Cytochrome P-450 CYP2C19 (genetics)
• Depressive Disorder (drug therapy, genetics)
• Female
• Genotype
• Humans
• Male
• Pharmacogenetics
• Receptor, Serotonin, 5-HT2A (genetics)
• Receptors, Kainic Acid (genetics)
• Retrospective Studies
• Serotonin Plasma Membrane Transport Proteins (genetics)
• Sertraline (therapeutic use)